Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 3, 2011, Pages 405-410

  Hashimoto, Kohei ^a   Masumori, Naoya ^a   Hashimoto, Jiro ^a   Takayanagi, Akio ^a   Fukuta, Fumimasa ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiandrogen; Castration resistant prostate cancer; Maximal androgen blockade; Prognosis; Testosterone

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION MONOTHERAPY; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; PNEUMONIA; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 79952368243     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq193     Document Type: Article

References (22)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
2. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy
3. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679-83.
4. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007;14:128-32.
5. Soga N, Arima K, Sugimura Y. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade. Jpn J Clin Oncol 2008;38:617-22.
6. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001;19:62-71.
7. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 2000;37:218-22.
8. Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, et al. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 2006;97:1184-9.
9. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159:149-53.
10. Fowler JE, Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995;154:448-53.
11. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006;176:1392-7; discussion 1397-8.
12. Isom-Batz G, Bianco FJ, Jr., Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935-7.
13. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7.
14. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007;52:696-701.
15. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573-8.
16. Furuya Y, Nozaki T, Nagakawa O, Fuse H. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002;49:85-90.
17. Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, et al. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 2008;15:472-80.
18. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 1993;71:1083-8.
19. Murphy JC, Srinivas S, Terris MK. Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. J Androl 2004;25:630-4.
20. Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006;98:563-72.
21. Ayub M, Levell MJ. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clin Endocrinol 1990;32:329-39.
22. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, et al. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol 2010;17:337-45.